The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...

Amy Nguyen Howell, MD, MBA, highlights the importance of data collection, analysis, and the new ICD-10-CMZ codes in understanding and resolving health disparities in diabetic macular edema patient ...

Hopes remain for Unity Biotechnology Inc.’s UBX-1325 in diabetic macular edema (DME) following a phase II miss in wet age-related macular degeneration (AMD), where data from part A of the study called ...

EyePoint Pharmaceuticals receives a reiterated sell rating due to ongoing clinical and commercial uncertainties despite recent progress in DME and wet AMD trials. Duravyu (EYP-1901) showed positive ...

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 3E10 vg/eye demonstrated strong signals of ...

Please provide your email address to receive an email when new articles are posted on . Improved tools are needed to collect real-world patient-reported outcomes in geographic atrophy. More data will ...

Patients with diabetic macular edema experienced visual acuity gains and reduced central subfield thickness after 2 years of treatment with Beovu, according to a press release from Novartis. Week 100 ...

- DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 - - New ...

President and Chief Executive Officer — Jay S. Duker, M.D. Chief Financial Officer — George O. Elston Chief Medical Officer — Ramiro Ribeiro, M.D. Management expects DuraVu to be the only tyrosine ...

--EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced details ...